SEC Tracker
Get the app

Radiopharm Theranostics RADX

Radiopharm completes FDA meeting for RAD101

Foreign issuer report

Form
6-K
Filed
Importance
Routine
  1. Completed End-of-Phase 2 meeting with FDA on Oct 5, 2026
  2. RAD101 shows 93% concordance with MRI in Phase 2b trial
  3. FDA meeting minutes expected within 30 days
  4. Partnership with Siemens Healthineers for Phase 3 trial

Written from the 6-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Radiopharm Theranostics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.